SCHEMBL22019039

SCHEMBL22019039

C#CCOc1ccc(NCC(=O)NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.37
ALDH1A1 P00352 5/20 0.37
GAA P10253 3/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
KMT2A Q03164 2/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
LMNA P02545 1/20 0.37
NLRP1 Q9C000 1/20 0.36
CA12 O43570 6/20 0.36
CA1 P00915 6/20 0.36
CA2 P00918 6/20 0.36
CA9 Q16790 6/20 0.36
PTPN11 Q06124 1/20 0.36
MAPK1 P28482 1/20 0.36
GSTP1 P09211 1/20 0.36
CA4 P22748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18025366 0.82 CYP17A1 (0.47) MAPTKMT2ACHRNB2CHRNB4CHRNA3
SCHEMBL11649697 0.79 ALDH1A1 (0.40) MAPTALDH1A1KMT2ALMNANLRP1
SCHEMBL4929584 0.79 MIF (0.44) MAPTALDH1A1GAAKMT2ALMNA
SCHEMBL5864432 0.78 ALDH1A1 (0.42) MAPTALDH1A1GAAKMT2ALMNA
SCHEMBL11650332 0.78 SMN1; SMN2 (0.44) MAPTALDH1A1KMT2ALMNAMAPK1
SCHEMBL9027360 0.77 LMNA (0.48) MAPTALDH1A1GAAKMT2ALMNA
SCHEMBL5664612 0.77 ALDH1A1 (0.46) MAPTALDH1A1KMT2ALMNACA12
SCHEMBL10126608 0.71 CA12 (0.55) CA12CA1CA2CA9PTPN11
SCHEMBL12837653 0.71 CTSS (0.52) ALDH1A1KMT2ACHRNB2CHRNB4CHRNA3
SCHEMBL14645383 0.71 PTPN11 (0.44) ALDH1A1KMT2ALMNACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10660968-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10660968-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A MAPT 2629/4885ALDH1A1 2438/4885GAA 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.